BB BIOTECH N

BB Biotech realised about CHF 280 million in Q3 by selling Crinetics Pharmaceuticals and Nuvalent and immediately deployed the proceeds into twelve new positions. Larger purchases included Biogen, Incyte and Axsome Therapeutics; Alnylam was re-added to the portfolio after a price drop. Other new investments cover advanced development programmes such as Kodiak Sciences, Summit Therapeutics, LB Pharmaceuticals and Bicara, as well as smaller starter positions in Alto Neuroscience, Yarrow Bioscience and Eupraxia. Private holdings remain limited, while BB Biotech sees room to expand positions if clinical evidence is positive; the stock has picked up momentum again after a period of consolidation. » Plus sur deraktionaer.de

BB Biotech expanded its portfolio by twelve new holdings in the third quarter and reinvested around CHF 280 million from takeovers. The new additions range from established biotech companies with product revenues to clinical-stage developers with upcoming milestones. The purchases aim to find stocks whose market valuations do not yet fully reflect their scientific, clinical and commercial potential. » Plus sur finanzen.net

BB Biotech recorded a profit of CHF 175 million in the third quarter, marking the second consecutive profitable quarter. The net asset value rose 5.6% in CHF during the quarter, and the company reports clinical and regulatory progress at portfolio companies. After the September correction, BB Biotech sees targeted buying opportunities in stocks whose prices have fallen despite unchanged clinical prospects; further milestones are expected in the fourth quarter. » Plus sur finanzen.net